Farmas USA

Alguien me puede decir q significa esto
http://www.diarioabierto.es/230024/la-cnmv-da-luz-verde-a-la-opa-de-exclusion-de-tavex
TAVEX

Pues que ofrecen 0,24€ por acción y una vez realizada la operación, va a dejar de cotizar en bolsa.
Puedes escoger entre aceptar esos 0,24€ o puedes no vender, pero si escoges esto último te arriesgas a no poder venderlas nunca más.

TAVEX

No venderlas nunca más o q la nueva empresa las haga subir hasta el cielo
TAvex

Van a dejar de cotizar, van a ser excluidas de la bolsa, así que lo de subirlas hasta el cielo no se va producir. Otra cosa es que te ofrecieran o un precio o un canje de acciones de tavex por las de la empresa que opa, pero no es el caso.

TAVEX

Tango69, tienes un rico hilo dedicado a TAVEX sobre el que llevan hablando de esto desde hace semanas un monton de compañeros en tu misma situacion

https://www.rankia.com/foros/bolsa/temas/1052911-cnmv-aviso-voy-forrar-tavex?page=248#respuesta_2587115

Acepta lo que os dan, olvida este valor ( que es un chicharro de mierda), no mires atras y alegrate de no haberlo perdido todo. 

Lo se framus pensé q aquí en este hilo podría conseguir más información
GRACIAS una vez mas

que conste que yo palme un -40% o asi en ese valor pero ampute en 2012 porque no le vi futuro. Ánimo.

AGEN........................parece que acerté también con esta..........

Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant
Date : 12/18/2014 @ 7:00AM
Source : GlobeNewswire Inc.
Stock : Agenus Inc. (MM) (AGEN)
Quote : 3.35 0.0 (0.00%) @ 4:00AM
Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant
Print
Alert
Antigenics (NASDAQ:AGEN)
Intraday Stock Chart
Today : Thursday 18 December 2014

Click Here for more Antigenics Charts.
GSK's ZOE-50 Phase 3 study meets primary endpoint of reducing the risk of shingles in people aged 50 and older
Agenus is entitled to receive royalties on potential commercial sales of HZ/su

Agenus Inc. (Nasdaq:AGEN), an immuno-oncology company developing a broad portfolio of checkpoint modulators (CPMs) and heat shock protein peptide-based vaccines as well as adjuvants, announced that its partner GlaxoSmithKline (NYSE:GSK) reported that the ZOE-50 Phase 3 study met its primary endpoint. Analysis of the primary endpoint showed that HZ/su reduced the risk of shingles by 97.2 per cent in adults aged 50 years and older compared to placebo.
HZ/su is a novel candidate vaccine that combines gE, a protein found on the varicella-zoster virus that causes shingles, with GSK's Adjuvant System, AS01B, which serves to stimulate a stronger immunological response to the vaccine. Agenus' QS-21 Stimulon® adjuvant is one of the key components of AS01, which is used in other vaccine candidates undergoing clinical development.

Agenus is entitled to receive royalties on potential commercial sales of HZ/su.

"We are thrilled with the results of this important study," said Garo Armen, Ph.D., Chief Executive Officer of Agenus, "The results indicate unprecedented protection against shingles. HZ/su is the second candidate vaccine containing QS-21 saponin to produce positive phase 3 results."

The study, which started in August 2010, is a randomized, placebo-controlled, multicenter, international study involving 16,136 adults aged 50 and older. An additional GSK trial to evaluate the ability of HZ/su to prevent shingles is underway in adults aged 70 and older (ZOE-70). This study will provide additional information on the efficacy of HZ/su vaccine candidate in preventing some of the complications of shingles, the most common being chronic neuropathic pain, also known as post-herpetic neuralgia (PHN)i.

Data from GSK's ZOE-50 study are expected to be presented at a forthcoming scientific conference and will be submitted for publication in a peer-reviewed journal.